In encouraging news regarding melanoma therapy, researchers found that a personalized vaccine continues to keep cancer cells in check four years after patients received it.
Scientific Publications
Eganelisib/Nivolumab Combo Shows Positive Responses in Head and Neck Carcinoma, Melanoma
Positive response and disease control rates were observed in 2 separate studies when patients with head and neck squamous cell carcinoma (HNSCC) and melanoma received the combination of eganelisib (IPI-549), a selective PI3K-? inhibitor, and nivolumab (Opdivo).
Deciding Between Adjuvant Targeted Therapy and Immunotherapy in BRAF+ Melanoma
When selecting between an adjuvant targeted therapy or immunotherapy for a patient with melanoma, it’s important to consider several factors, including the biologic behavior of the tumor, any comorbidities, toxicities, and patient concerns, according to Reinhard Dummer, MD.
Improved dermoscopy training in residency should be prioritized
Dermoscopy training and education should be prioritized in resident education to increase melanoma detection, according to a study published in JAMA Dermatology.